Keeping Up With The Rapid Emergence of Strategies for Advanced Renal Cell Carcinoma

Keeping Up With the Rapid Emergence of Strategies for Advanced Renal Cell Carcinoma

ReachMD Healthcare Image
RestartResume

Watch this educational activity to learn about the latest guideline-recommended first-line and later-line treatments for advanced renal cell carcinoma (RCC), as well as strategies to manage adverse (AEs) events of novel therapies. 

Available credits: 1.00

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Watch this educational activity to learn about the latest guideline-recommended first-line and later-line treatments for advanced renal cell carcinoma (RCC), as well as strategies to manage adverse (AEs) events of novel therapies. 

  • Disclosure of Conflicts of Interest

    Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

    Mary Weinstein Dunn, MSN, NP-C, OCN, RN, has no relevant financial relationships to disclose

    The planners and content peer reviewers from Partners for Advancing Clinical Education, Practicing Clinicians Exchange, and Smart Patients do not have any relevant financial relationships to disclose.

  • Target Audience

    Oncology NPs, PAs, and nurses

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Apply guideline-recommended first- and subsequent-line treatments for advanced RCC
    • Manage AEs of novel therapies for RCC based on guideline recommendations
    • Integrate patient education and feedback to optimize patient experiences during treatment and survivorship
  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement
    In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    ANCC Credit Designation
    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.00 contact hours. 

    AAPA Credit Designation

    Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until April 10, 2024. PAs should only claim credit commensurate with the extent of their participation.  

    IPCE Credit Designation

    This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change. 

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

  • Provider(s)/Educational Partner(s)

    Provided by Partners for Advancing Clinical Education (PACE) in partnership with Smart Patients

  • Commercial Support

    Supported by an educational grant from Exelixis, Inc.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free